Diabetes mellitus with poor glycemic control is a risk factor for pneumonia in COPD.

Background: Pneumonias are events of great prognostic significance in COPD, so it is important to identify predictive factors.

Objective: To determine whether poor glycemic control is related to an increased risk of pneumonia in COPD.

Method: A historical cohort study conducted in a COPD clinic.

Incidence and profile of severe exacerbations of chronic obstructive pulmonary disease due to biomass smoke or tobacco.

Introduction And Objectives: Stable chronic obstructive pulmonary disease (COPD) caused by biomass smoke (B-COPD) has some differences from tobacco-induced-COPD (T-COPD), but acute exacerbations (AECOPD) have not been well characterized in B-COPD.

Objective: To compare the incidence, characteristics and outcomes of AECOPD in B-COPD with those of T-COPD.

Methods: A retrospective observational study that included consecutive patients seen at a specialized COPD clinic (2008-2021).

Trajectories of Severe Exacerbations of Chronic Obstructive Pulmonary Disease and Their Relationship with Mortality Risk.

Purpose: Acute exacerbations of COPD (AECOPD) are important factors contributing to mortality risk. The rate of exacerbations varies overtime. An inconsistent pattern of exacerbation occurrence is a common finding.

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome.

Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months.

A new, three-dimensional approach to the GOLD COPD assessment tool.

Background: The 2-dimensional, 4-quadrant 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD A-D assessment tool (GOLD) does not include lung function variables to classify patients into different risk groups. The previous 2011 tool (GOLD) classified cases in the upper-quadrants (higher risk groups) regardless of whether they had a history of exacerbations or worse lung function. We hypothesized that a modified, three-dimensional classification (GOLD) that separately includes assessment of lung function and exacerbations history would improve the ability to predict adverse events.

Efficacy of mepolizumab in usual clinical practice and characteristics of responders.

Background: Severe eosinophilic asthma is a high-burden disease. Mepolizumab has been effective in several randomized clinical trials. However, such success might not be applicable to patients treated in usual clinical practice.

Phenotype-Guided Asthma Therapy: An Alternative Approach to Guidelines.

Despite recent advances in therapy, a substantial proportion of asthmatics remain not well controlled. The classical stepwise approach to pharmacological therapy in adult asthma recommends that treatment is progressively stepped up by increasing the inhaled corticosteroid (ICS) dose or by adding another controller medication- to achieve symptom control and reduce the risk of exacerbations, and stepped down after a period of control. In general, asthma guideline recommendations do not reflect that there are significant differences between ICS in terms of potency.